Whereas ERBB2 activating mutations are already recognized as important biomarkers in NSCLC, we identified ERBB2 mutations across solid tumor types with breast, CRC, bladder, and GEC cancers together accounting for 50.4% (4,301/8,526) of ERBB2mut tumors in our cohort. Here, ERBB2 is linked to non-small cell lung carcinoma.